Keywords: fda, warns, lilly, over, axid, claims, eli
FDA Warns Lilly Over Axid Claims
Article | 01 August 1994
Eli Lilly's promotion to managed care customers of its Axid (nizatidine) H2 antagonist for gastro-esophageal reflux diseases is misleading, according ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
